| Slide | |
| Credits | 1 |
| Facts | 2 |
| 3 | |
| Guidelines | 4 |
| 5 | |
| Guideline Compliance | 6 |
| Guideline Problems | 7 |
| Pathophysiology | 8 |
| Airway Inflammation | 9 |
| NHLBI: Key Indicators | 10 |
| 11 | |
| Historical Features | 12 |
| 13 | |
| NHLBI: Key Indicators | 14 |
| Physical Exam | 15 |
| NHLBI: Key Indicators | 16 |
| Spirometry | 17 |
| 18 | |
| Spirometry in Asthma | 19 |
| Spirometry | 20 |
| Peak Flow Monitoring | 21 |
| Differential Diagnosis | 22 |
| 23 | |
| Other Studies | 24 |
| Airway Hyper-responsiveness | 25 |
| Methacholine Challenge | 26 |
| Bronchoprovocation | 27 |
| Other Studies | 28 |
| Vocal Cord Dysfunction | 29 |
| Asthma Therapy | 30 |
| Drug Therapy | 31 |
| Classification of Asthma | 32 |
| 33 | |
| Mild Intermittent | 34 |
| 35 | |
| Classification of Asthma | 36 |
| Mild Persistent | 37 |
| 38 | |
| Classification of Asthma | 39 |
| Moderate Persistent | 40 |
| 41 | |
| 42 | |
| Classification of Asthma | 43 |
| Severe Persistent | 44 |
| 45 | |
| Beta Agonists | 46 |
| Inhaled Corticosteroids | 47 |
| 48 | |
| Toxicity of Inhaled Steroids | 49 |
| Therapy Failure | 50 |
| Leukotriene Inhibitors | 51 |
| Reference | 52 |
| 53 | |
| Patient Characteristics | 54 |
| Classification of Asthma | 55 |
| Conclusions | 56 |
| 57 | |
| Long Acting Beta Agonists | 58 |